top of page
Search

Rapivab

Updated: Feb 8, 2022

Biocelect is excited to announce its partnership with BioCryst Pharmaceuticals Inc. As a result Biocelect is now the exclusive distributor in Australia for Rapivab (peramivir) a neuraminidase inhibitor for the treatment of acute influenza. An exciting addition to our expanding product range.

Rapivab is the only TGA approved intravenous influenza antiviral available on the current market.







 
 
 

Comments

Biocelect Logo_Colour.png

© 2025 Biocelect

Product, Medical & Patient Enquiries -  Phone: +61 1300 848 628 Email: patientsafety@biocelect.com

General Enquiries & Ordering Information - Phone: +61 1300 907 411 Email: info@biocelect.com

All phone numbers are free call from Australia & New Zealand 

Australian Office: Level 4, 143 Macquarie Street, Sydney NSW 2000, Australia

Registered Office Australia: Level 29, 66 Goulburn Street, Sydney NSW 2000, Australia

Registered Office New Zealand: Level 5, Wynn Williams House, 47 Hereford Street, Christchurch 8013, New Zealand

Biocelect acknowledges the Traditional Custodians of Australia and their continued connection to land,
sea and community. We pay our respects to the Elders, emerging, past and present. ​

Privacy Policy

Last Updated 12th February 2025

  • linkedin
bottom of page